ACARIZAX 12 SQ-HDM oral lyophilisate *

  • Company:

    ALK-Abello Ltd
  • Status:

    No Recent Update
  • Legal Category:

    Product subject to medical prescription which may be renewed (B)
  • This medicinal product is subject to additional monitoring.

    *Additional information is available within the SPC or upon request to the company

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 09 July 2021

File name

SPC_IE_PA1255-010-001-Acarizax_Jun2021_1625823154.pdf

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

All relevant sections updated to include treatment of allergic rhinitis in adolescents

Updated on 09 July 2021

File name

PIL_IE_Acarizax_Jun2021_1625823033.pdf

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 2 - use in children and adolescents
  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

PIL updated to include treatment of allergic rhinitis in adolescents

Updated on 27 July 2020

File name

SPC_IE_PA1255-010-001-Acarizax_May2020_1595856952.pdf

Reasons for updating

  • Change to section 9 - Date of first authorisation/renewal of the authorisation

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Minor wording changes submitted as part of renewal

Updated on 27 July 2020

File name

PIL_IE_Acarizax_May2020_1595856893.pdf

Reasons for updating

  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

Minor wording changes submitted as part of the renewal

Updated on 16 June 2020

File name

SPC_IE_PA1255-010-001-Acarizax_Nov2019_1592301030.pdf

Reasons for updating

  • New SPC for medicines.ie

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 16 June 2020

File name

SPC_IE_PA1255-010-001-Acarizax_Nov2019_1592300578.pdf

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 16 June 2020

File name

PIL_IE_Acarizax_Nov2019_1592300544.pdf

Reasons for updating

  • New PIL for new product